Full Text Journal Articles by
Author Howard H Bailey

Advertisement

Find full text journal articles






A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol.

Howard H Bailey, Jeremy J Johnson, Taja Lozar, Cameron O Scarlett, Barbara W Wollmer, KyungMann Kim, Thomas Havinghurst, Nihal Ahmad,

Resveratrol (3,4,5-trihydroxystilbene) is a naturally occurring phytoalexin with purported health-promoting effects, but with limited oral bioavailability. Our prior murine modeling research observed enhanced resveratrol bioavailability with piperine co-administration. In this study, single-dose pharmacokinetics of resveratrol with or without piperine and the associated toxicities were studied on a cohort of healthy ... Read more >>

Eur J Cancer Prev (European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP))
[2021, 30(3):285-290]

Cited: 0 times

View full text PDF listing >>



A phase II randomized placebo-controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance.

David Jarrard, Mikolaj Filon, Wei Huang, Tom Havighurst, Katina DeShong, KyungMann Kim, Badrinath R Konety, Daniel Saltzstein, Hasan Mukhtar, Barbara Wollmer, Chen Suen, Margaret G House, Howard L Parnes, Howard H Bailey,

<h4>Introduction or objective</h4>Men with favorable-risk prostate cancer (PCa) on active surveillance may benefit from intervention strategies to slow or prevent disease progression and the need for definitive treatment. Pomegranate and its extracts have shown antiproliferative and proapoptotic effects in cell lines and animal models, but its effect on human prostate ... Read more >>

Prostate (The Prostate)
[2021, 81(1):41-49]

Cited: 1 time

View full text PDF listing >>



Advertisement

Oncologic Implications of Chronic Hepatitis C Virus Infection.

Jessica P Hwang, Noelle K LoConte, John P Rice, Lewis E Foxhall, Erich M Sturgis, Janette K Merrill, Harrys A Torres, Howard H Bailey,

Chronic hepatitis C virus (HCV) infection increases the risk for several types of cancer, including hepatocellular carcinoma (HCC) and B-cell non-Hodgkin lymphoma, as primary and second primary malignancies. HCV-infected patients with cancer, particularly those undergoing anticancer therapy, are at risk for development of enhanced HCV replication, which can lead to ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2019, 15(12):629-637]

Cited: 1 time

View full text PDF listing >>



A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers.

Jill M Kolesar, Shannon Andrews, Heather Green, Tom C Havighurst, Barbara W Wollmer, Katina DeShong, Douglas E Laux, Helen Krontiras, Donald D Muccio, KyungMann Kim, Clinton J Grubbs, Margaret G House, Howard L Parnes, Brandy M Heckman-Stoddard, Howard H Bailey,

9cUAB30 is a synthetic analogue of 9-cis retinoic acid with chemoprevention activity in cell lines and animal models. The purpose of this phase I placebo-controlled, double-blinded, dose escalation study of 9cUAB30 was to evaluate its safety, pharmacokinetics, and determine a dose for future phase II studies. Participants received a single ... Read more >>

Cancer Prev Res (Phila) (Cancer prevention research (Philadelphia, Pa.))
[2019, 12(12):903-912]

Cited: 0 times

View full text PDF listing >>



A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors.

Christos E Kyriakopoulos, Amy M Braden, Jill M Kolesar, Jens C Eickhoff, Howard H Bailey, Jennifer Heideman, Glenn Liu, Kari B Wisinski,

Background A wide variety of human cancers exhibit dysregulated c-Met activity that has implications in oncogenesis. Phosphorylation of c-Met results in activation of the PI3K/AKT/mTOR pathway. Combined blockade of c-Met and mTOR pathways has shown efficacy in preclinical studies. Tivantinib is a c-Met inhibitor and temsirolimus is a selective mTOR ... Read more >>

Invest New Drugs (Investigational new drugs)
[2017, 35(3):290-297]

Cited: 10 times

View full text PDF listing >>



Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

David Jarrard, Badrinath Konety, Wei Huang, Tracy Downs, Jill Kolesar, Kyung Mann Kim, Tom Havighurst, Joel Slaton, Margaret G House, Howard L Parnes, Howard H Bailey,

<h4>Introduction and objectives</h4>Prostate cancer (PCa) represents an important target for chemoprevention given its prolonged natural history and high prevalence. Epidemiologic and laboratory data suggest that vitamin D and genistein (soy isoflavone) may decrease PCa progression. The effect of vitamin D on prostate epithelial cell proliferation and differentiation is well documented ... Read more >>

Am J Clin Exp Urol (American journal of clinical and experimental urology)
[2016, 4(2):17-27]

Cited: 6 times

View full text PDF listing >>



Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy.

Jason R Gee, Daniel R Saltzstein, Edward Messing, KyungMann Kim, Jill Kolesar, Wei Huang, Thomas C Havighurst, Linda Harris, Barbara W Wollmer, David Jarrard, Margaret House, Howard Parnes, Howard H Bailey,

Epidemiologic, preclinical, and early phase I studies of the cruciferous vegetable bioactive metabolite, 3,3'-diindolylmethane (DIM), support its potential prostate cancer chemopreventive ability. We performed a multicenter, double-blind, placebo-controlled trial of DIM in patients diagnosed with prostate cancer and scheduled for radical prostatectomy. A total of 45 patients with organ-confined prostate ... Read more >>

Eur J Cancer Prev (European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP))
[2016, 25(4):312-320]

Cited: 3 times

View full text PDF listing >>



American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

Howard H Bailey, Linus T Chuang, Nefertiti C duPont, Cathy Eng, Lewis E Foxhall, Janette K Merrill, Dana S Wollins, Charles D Blanke,

American Society of Clinical Oncology (ASCO), the leading medical professional oncology society, is committed to lessening the burden of cancer and as such will promote underused interventions that have the potential to save millions of lives through cancer prevention. As the main providers of cancer care worldwide, our patients, their ... Read more >>

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2016, 34(15):1803-1812]

Cited: 28 times

View full text PDF listing >>



Pilot study of intravenous melphalan combined with continuous infusion L-S,R-buthionine sulfoximine for children with recurrent neuroblastoma.

Clarke P Anderson, Katherine K Matthay, John P Perentesis, Joseph P Neglia, Howard H Bailey, Judith G Villablanca, Susan Groshen, Beth Hasenauer, John M Maris, Robert C Seeger, C Patrick Reynolds,

<h4>Purpose</h4>To evaluate BSO-mediated glutathione (GSH) depletion in combination with L-PAM for children with recurrent or refractory high-risk neuroblastoma (NB) as a means to enhance alkylator sensitivity.<h4>Procedure</h4>This pilot study (NCI #T95-0092) administered L-S,R-buthionine sulfoximine (BSO) as a bolus followed by 72 hr continuous infusion of either 0.75 g/m(2)/hr (level 1) or ... Read more >>

Pediatr Blood Cancer (Pediatric blood & cancer)
[2015, 62(10):1739-1746]

Cited: 15 times

View full text PDF listing >>



Serving the State Through Medical Research.

Howard H Bailey, Robert N Golden,

WMJ (WMJ : official publication of the State Medical Society of Wisconsin)
[2015, 114(6):274-275]

Cited: 0 times

View full text PDF listing >>



Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Carol J Fabian, Bruce F Kimler, Carola M Zalles, Teresa A Phillips, Trina Metheny, Brian K Petroff, Thomas C Havighurst, KyungMann Kim, Howard H Bailey, Brandy M Heckman-Stoddard,

The purpose of this study was to assess the feasibility of using the selective estrogen receptor modulator (SERM) acolbifene as a breast cancer prevention agent in premenopausal women. To do so, we assessed change in proliferation in benign breast tissue sampled by random periareolar fine-needle aspiration (RPFNA) as a primary ... Read more >>

Cancer Prev Res (Phila) (Cancer prevention research (Philadelphia, Pa.))
[2015, 8(12):1146-1155]

Cited: 5 times

View full text PDF listing >>



Epidemiologic factors and urogenital infections associated with preterm birth in a midwestern U.S. population.

William A Agger, Danish Siddiqui, Steven D Lovrich, Steven M Callister, Andrew J Borgert, Kenneth W Merkitch, Tina C Mason, Dennis J Baumgardner, James K Burmester, Sanjay K Shukla, Joseph D Welter, Katharina S Stewart, M J Washburn, Howard H Bailey,

<h4>Objective</h4>To correlate epidemiologic factors with urogenital infections associated with preterm birth.<h4>Methods</h4>Pregnant women were sequentially included from four Wisconsin cohorts: large urban, midsize urban, small city, and rural city. Demographic, clinical, and current pregnancy data were collected. Cervical and urine specimens were analyzed by microscopy, culture, and polymerase chain reaction for ... Read more >>

Obstet Gynecol (Obstetrics and gynecology)
[2014, 124(5):969-977]

Cited: 15 times

View full text PDF listing >>



Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Gregory A Masters, Lada Krilov, Howard H Bailey, Marcia S Brose, Harold Burstein, Lisa R Diller, Don S Dizon, Howard A Fine, Gregory P Kalemkerian, Mark Moasser, Michael N Neuss, Steven J O'Day, Olatoyosi Odenike, Charles J Ryan, Richard L Schilsky, Gary K Schwartz, Alan P Venook, Sandra L Wong, Jyoti D Patel,

J Clin Oncol (Journal of clinical oncology : official journal of the American Society of Clinical Oncology)
[2015, 33(7):786-809]

Cited: 51 times

View full text PDF listing >>



Cancer chemoprevention is not a failure.

Vaqar Mustafa Adhami, Howard H Bailey, Hasan Mukhtar,

Carcinogenesis (Carcinogenesis)
[2014, 35(9):2154-2155]

Cited: 11 times

View full text PDF listing >>



A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer.

Kari B Wisinski, Wendy M Ledesma, Jill Kolesar, George Wilding, Glenn Liu, Jeffrey Douglas, Anne M Traynor, Mark Albertini, Daniel Mulkerin, Howard H Bailey,

<h4>Background</h4>The objective of this study was to determine the maximum tolerated dose and safety of LR-103, a Vitamin D analogue, in patients with advanced cancer.<h4>Methods</h4>In Step A, patients received oral LR-103 once daily in 14-day cycles with intra-patient dose escalation per accelerated dose escalation design. Dose limiting toxicity for Step ... Read more >>

J Oncol Pharm Pract (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners)
[2015, 21(6):416-424]

Cited: 0 times

View full text PDF listing >>



Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer.

Jill M Kolesar, Marcia Pomplun, Tom Havighurst, Jeanne Stublaski, Barbara Wollmer, KyungMann Kim, Joseph A Tangrea, Howard L Parnes, Margaret G House, Jason Gee, Edward Messing, Howard H Bailey,

<h4>Background</h4>The isoflavone genistein, a natural soy product with receptor tyrosine kinase-inhibiting activity, as well as phytoestrogenic and other potential anticarcinogenic effects, is being studied as an anticancer agent. Since isoflavones are commonly consumed in food products containing soy proteins, a method to control for baseline isoflavone consumption is needed.<h4>Methods</h4>HPLC was ... Read more >>

J Oncol Pharm Pract (Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners)
[2015, 21(2):128-131]

Cited: 0 times

View full text PDF listing >>



A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors.

Dustin A Deming, Jacob Ninan, Howard H Bailey, Jill M Kolesar, Jens Eickhoff, Joel M Reid, Matthew M Ames, Renee M McGovern, Dona Alberti, Rebecca Marnocha, Igor Espinoza-Delgado, John Wright, George Wilding, William R Schelman,

<h4>Background</h4>Accumulating evidence shows evidence of efficacy with the combination of vorinostat and bortezomib in solid tumors. We previously examined a once-daily continuous dosing schedule of vorinostat in combination with bortezomib which was well tolerated in cycles 1 and 2; however, there was concern regarding the tolerability through multiple cycles. This ... Read more >>

Invest New Drugs (Investigational new drugs)
[2014, 32(2):323-329]

Cited: 16 times

View full text PDF listing >>



A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies.

William R Schelman, Anne M Traynor, Kyle D Holen, Jill M Kolesar, Steven Attia, Tien Hoang, Jens Eickhoff, Zhisheng Jiang, Dona Alberti, Rebecca Marnocha, Joel M Reid, Matthew M Ames, Renee M McGovern, Igor Espinoza-Delgado, John J Wright, George Wilding, Howard H Bailey,

<h4>Background</h4>A phase I study to assess the maximum-tolerated dose (MTD), dose-limiting toxicity (DLT), pharmacokinetics (PK) and antitumor activity of vorinostat in combination with bortezomib in patients with advanced solid tumors.<h4>Methods</h4>Patients received vorinostat orally once daily on days 1-14 and bortezomib intravenously on days 1, 4, 8 and 11 of a ... Read more >>

Invest New Drugs (Investigational new drugs)
[2013, 31(6):1539-1546]

Cited: 17 times

View full text PDF listing >>



Green tea polyphenols and cancer chemoprevention of genitourinary cancer.

Howard H Bailey, Hasan Mukhtar,

Green tea, which has higher concentrations of polyphenols than other teas, has been correlated with reduced risk of various malignancies with most data supporting a potential protective role in prostate neoplasia. Preclinical studies over the last 25 years implicate constituent green tea catechins, epigallocatechin-3-gallate (EGCG) being the predominant form, as ... Read more >>

Am Soc Clin Oncol Educ Book (American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting)
[2013, :92-96]

Cited: 6 times

View full text PDF listing >>



Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes.

Jill M Kolesar, Anne M Traynor, Kyle D Holen, Tien Hoang, Songwon Seo, Kyungmann Kim, Dona Alberti, Igor Espinoza-Delgado, John J Wright, George Wilding, Howard H Bailey, William R Schelman,

<h4>Introduction</h4>Vorinostat is a small molecule inhibitor of class I and II histone deacetylase enzymes which alters the expression of target genes including the cell cycle gene p21, leading to cell cycle arrest and apoptosis.<h4>Methods</h4>Patients enrolled in a phase I trial were treated with vorinostat alone on day 1 and vorinostat ... Read more >>

Cancer Chemother Pharmacol (Cancer chemotherapy and pharmacology)
[2013, 72(3):661-667]

Cited: 2 times

View full text PDF listing >>



Predictors of willingness to participate in window-of-opportunity breast trials.

Kari B Wisinski, Adrienne Faerber, Stephanie Wagner, Thomas C Havighurst, Jane A McElroy, Kyungmann Kim, Howard H Bailey,

<h4>Objective</h4>We conducted a pilot survey to evaluate breast cancer patients' willingness to participate in a preoperative chemoprevention (ie, window-of-opportunity) study. Design A 27-question written survey was developed and administered to participants. Setting A breast cancer specialty clinic at the University of Wisconsin Hospital and Clinics. Participants 30 adult patients with ... Read more >>

Clin Med Res (Clinical medicine & research)
[2013, 11(3):107-112]

Cited: 4 times

View full text PDF listing >>



Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care?

Gabrielle B Rocque, Anne E Barnett, Lisa C Illig, Jens C Eickhoff, Howard H Bailey, Toby C Campbell, James A Stewart, James F Cleary,

<h4>Introduction</h4>Despite advances in the care of patients with cancer over the last 10 years, cancer remains the second leading cause of death in the United States. Many patients receive aggressive, in-hospital end-of-life care at high cost. There are few data on outcomes after unplanned hospitalization of patients with metastatic cancer.<h4>Methods</h4>In ... Read more >>

J Oncol Pract (Journal of oncology practice)
[2013, 9(1):51-54]

Cited: 52 times

View full text PDF listing >>



A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

Sarah M Kreul, Tom Havighurst, KyungMann Kim, Eneida A Mendonça, Gary S Wood, Stephen Snow, Abbey Borich, Ajit Verma, Howard H Bailey,

Decreasing the incidence of nonmelanoma skin cancer (NMSC) is of great importance in regards to future healthcare services. Given the previously reported preventive effects of α-difluoromethylornithine (DFMO) in skin and colon cancer trials, we determined appropriate cause to update the clinical data on the subjects from the recently reported randomized, ... Read more >>

Cancer Prev Res (Phila) (Cancer prevention research (Philadelphia, Pa.))
[2012, 5(12):1368-1374]

Cited: 12 times

View full text PDF listing >>



Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network.

Vaishalee P Kenkre, Walter L Long, Jens C Eickhoff, Jules H Blank, Thomas A McFarland, Wayne Bottner, Hamied Rezazedeh, Jae E Werndli, Howard H Bailey, Brad S Kahl,

Mantle cell lymphoma (MCL) is challenging to manage, with a median survival of 3-5 years. While intensive strategies are often appropriate for younger patients, these approaches are often not appropriate for older patients. In 2006, we reported our initial results using modified R-hyperCVAD (rituximab with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and ... Read more >>

Leuk Lymphoma (Leukemia & lymphoma)
[2011, 52(9):1675-1680]

Cited: 26 times

View full text PDF listing >>



Enhancing the bioavailability of resveratrol by combining it with piperine.

Jeremy J Johnson, Minakshi Nihal, Imtiaz A Siddiqui, Cameron O Scarlett, Howard H Bailey, Hasan Mukhtar, Nihal Ahmad,

<h4>Scope</h4>Resveratrol (3,5,4'-trihydroxystilbene) is a phytoalexin shown to possess a multitude of health-promoting properties in pre-clinical studies. However, the poor in vivo bioavailability of resveratrol due to its rapid metabolism is being considered as a major obstacle in translating its effects in humans. In this study, we examined the hypothesis that ... Read more >>

Mol Nutr Food Res (Molecular nutrition & food research)
[2011, 55(8):1169-1176]

Cited: 111 times

View full text PDF listing >>



Advertisement

Disclaimer
1.0676 s